Intertwined Biosciences, a biotechnology startup developing an artificial intelligence-powered platform to discover new human therapies by studying biological adaptations across species, has secured pre-seed financing from Boost VC, Plug and Play Tech Center, and C10 Labs. The company announced the closing of the financing round as it works to build an AI-native discovery system designed to identify disease-resistance mechanisms found in animals and translate those insights into potential therapeutic applications.

Founded by Max Rye and Evan Appleton, Intertwined Biosciences is focused on a new approach to drug discovery that combines evolutionary biology, artificial intelligence, and experimental science. The company’s platform is designed to analyze biological traits that allow certain species to survive challenging conditions and identify mechanisms that could potentially be adapted for human medicine.

Boost VC participated in Intertwined Biosciences’ pre-seed financing. The venture capital firm invests in early-stage technology companies, including startups working in deep technology, artificial intelligence, and science-driven innovation. Its investment supports Intertwined Biosciences’ effort to develop computational tools for discovering new therapeutic opportunities.

Plug and Play Tech Center also invested in the company’s pre-seed round. The global innovation platform works with startups, corporations, and investors across multiple industries, including healthcare and biotechnology. Its participation reflects increasing interest in companies applying artificial intelligence to accelerate scientific discovery and medical innovation.

C10 Labs joined as another investor in the financing. The venture studio and investment firm focuses on supporting technology companies and founders building solutions in emerging areas. C10 Labs’ investment adds support to Intertwined Biosciences as it develops its AI-based approach to understanding biological systems.

Intertwined Biosciences is building what it calls a “Virtual Immune Cell,” an AI-native discovery system intended to identify biological mechanisms associated with disease resistance and guide therapeutic development. The company’s technology combines computational models with laboratory validation to explore how naturally occurring adaptations across species may reveal new approaches for treating human diseases.

The company’s scientific vision is based on the idea that evolution has produced a wide range of biological solutions that could provide insights into human health. Some animals have developed extraordinary abilities, including resistance to certain diseases, unusual immune responses, and adaptations to extreme environments. Intertwined Biosciences aims to use artificial intelligence to study these characteristics and identify patterns that could inform future medicines.

The startup’s platform is positioned at the intersection of artificial intelligence and biotechnology, two areas that have attracted significant investment as researchers look for faster and more efficient ways to discover treatments. Traditional drug discovery can require years of research and substantial resources, while AI-driven approaches aim to improve the process by identifying promising biological targets earlier.

Intertwined Biosciences is based at LabCentral in Kendall Square, a biotechnology hub that provides laboratory space and resources for emerging life sciences companies. The company’s acceptance into LabCentral provides access to scientific infrastructure and a community of biotech startups working on innovative research programs.

The company was also selected for the second cohort of the AI BioHub accelerator, a program focused on supporting AI-native biotechnology startups. Participation in the accelerator is intended to help companies integrate machine learning approaches with laboratory research and advance the development of new biotechnology platforms.

Intertwined Biosciences is led by Max Rye, who serves as CEO and co-founder, and Evan Appleton, who serves as chief scientific officer and co-founder. Rye previously co-founded TurtleTree, a biotechnology company that raised more than $40 million and focused on developing advanced biomanufacturing capabilities. Appleton has contributed to research in areas including machine-guided cell engineering.

The company’s financing comes as artificial intelligence continues to reshape biotechnology research. Investors are increasingly backing startups that combine machine learning with biological data, seeking new ways to accelerate the identification of therapeutic candidates and improve understanding of complex biological systems.

Intertwined Biosciences plans to use its pre-seed financing to continue building its AI discovery platform, expand its scientific capabilities, and advance research into evolution-inspired therapies. The company aims to create technology that can uncover biological insights hidden within nature and translate them into new approaches for human health.

With backing from Boost VC, Plug and Play Tech Center, and C10 Labs, Intertwined Biosciences is positioning itself as an emerging company in AI-driven biotechnology. By combining evolutionary insights, artificial intelligence, and experimental biology, the startup is seeking to develop a new pathway for discovering future medicines.

Related Articles